Targeting IL-23 in psoriasis: current perspectives

References

• NestleFOKaplanDHBarkerJPsoriasisN Engl J Med200936149650919641206
   PubMed Web of Science ®Google Scholar
• FitchEHarperEScortsevaIKurtzSEBlauveltAPathophysiology of psoriasis recent advances on IL-23 and Th17 cytokinesCurr Rheumatol Rep2007946146718177599
   PubMedGoogle Scholar
• Di MeglioPNestleFOThe role of IL-23 in the immunopathogenesis of psoriasisF1000 Biol Rep201024020948793
   PubMedGoogle Scholar
• TengMWBowmanEPMcElweeJJIL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseasesNat Med2015262533
   Google Scholar
• TangCChenSQianHHuangWInterleukin-23: as a drug target for autoimmune inflammatory diseasesImmunology201213511212422044352
   PubMed Web of Science ®Google Scholar
• DuvalletESemeranoLAssierEFalgaroniGBoissierMCInterleukin-23: a key cytokine in inflammatory diseasesAnn Med20114350351121585245
   PubMed Web of Science ®Google Scholar
• OppmannBLesleyRBlomBNovel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12Immunity20001371572511114383
   PubMed Web of Science ®Google Scholar
• ParhamCChiricaMTimansJA receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23RJ Immunol2002168699708
   Web of Science ®Google Scholar
• LevinAGottliebABSpecific targeting of interleukin-23p19 as effective treatment for psoriasisJ Am Acad Dermatol20147055556124373779
   PubMed Web of Science ®Google Scholar
• ZhengTDanilenkoDMValdezPInterleukin-22 a TH17 cytokine mediates IL-23-induced dermal inflammation and acanthosisNature200744564865117187052
   PubMed Web of Science ®Google Scholar
• LeeETrepicchioWLOestreicherJLIncreased expression of interleukin 23p19 and p40 in lesional skin of patients with psoriasis vulgarisJ Exp Med200419912513014707118
   PubMed Web of Science ®Google Scholar
• PiskinGSylva-SteenlandRMBosJDTeunisenMBIn vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions; enhanced expression in psoriatic skinJ Immunol20061761908191516424222
   PubMed Web of Science ®Google Scholar
• ElderJTBruceATGudjonssonJEMolecular dissection of psoriasis integrating genetics and biologyJ Invest Dermatol2010130213226
   Web of Science ®Google Scholar
• NairRPStuartPEKullavanijayaPGenetic evidence for involvement of the IL-23 pathway in Thai psoriaticsArch Dermatol2010302139143
   Google Scholar
• NakajimaKKandaTTakaishiMDistinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse modelJ Immunol20111864481448921346238
   PubMed Web of Science ®Google Scholar
• LowesMARusselCBMartinDAKruegerJGThe IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responsesTrends Immunol20133417418123291100
   PubMed Web of Science ®Google Scholar
• PiskinGTursenUSylva-SteenlandRMBosJDTeunissenMBClinical improvement in chronic plaque-psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-gamma inducers – IL-12, IL-18 and IL-23Exp Dermatol20041376476915560760
   PubMed Web of Science ®Google Scholar
• GottliebABChamianFMasudSTNF inhibition rapidly downregulates multiple proinflammatory pathways in psoriasis plaquesJ Immunol20051752721272916081850
   PubMed Web of Science ®Google Scholar
• McGeachyMJChenYTatoCMThe interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivoNat Immunol20091031432419182808
   PubMed Web of Science ®Google Scholar
• PappKAGriffithsCEGordonKLong-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-upBr J Dermatol201316884485423301632
   PubMed Web of Science ®Google Scholar
• LeonardiCLKimballABPappKAEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)Lancet20083711665167418486739
   PubMed Web of Science ®Google Scholar
• PappKALangleyRGLebwohlMEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)Lancet20083711675168418486740
   PubMed Web of Science ®Google Scholar
• TraczewskiPRudnickaLBriakinumab for the treatment of plaque psoriasisBioDrugs20122692022077474
   PubMed Web of Science ®Google Scholar
• GordonABLeonardiCKerdelFMehlisSOldsMWilliamsDAA phase III, randomized controlled trial of the fully human IL12/23 mAb briakinumab in moderate-to-severe psoriasisJ Invest Dermatol201213230431422011907
   PubMed Web of Science ®Google Scholar
• GaspariAATyringSNew and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitorsDermatol Ther20152817919326201310
   PubMed Web of Science ®Google Scholar
• TonelGConradCLaggnerUCutting edge: a critical functional role for IL-23 in psoriasisJ Immunol20101855688569120956338
   PubMed Web of Science ®Google Scholar
• KhaderSAPearlJESakamotoKIL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is availableJ Immunol200517578879516002675
   PubMed Web of Science ®Google Scholar
• DongJGoldbergGNew biologics in psoriasis: an update on IL-23 and IL-17 inhibitorsCutis20179912312728319618
   PubMed Web of Science ®Google Scholar
• GordonKBDuffinKCBissonetteRA phase 2 trial of guselkumab versus adalimumab for plaque psoriasisN Engl J Med201537313614426154787
   PubMed Web of Science ®Google Scholar
• BlauveltAPappKKGriffithsCEEfficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for continuous treatment of patients with moderate-to-severe psoriasis: results from the phase III, double blinded, placebo and active comparator controlled VOYAGE I trialJ Am Acad Dermatol20177640541728057360
   PubMed Web of Science ®Google Scholar
• ReichKArmstrongAWFoleyPEfficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate-to-severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blinded, placebo and active comparator controlled VOYAGE II trialJ Am Acad Dermatol20177641843128057361
   PubMed Web of Science ®Google Scholar
• LangleyRGTsaiTFFlavinSEfficacy and safety of guselkumab in patients with psoriasis with inadequate response to ustekinumab: results of the randomized, double-blind, phase 3 NAVIGATE trialBr J Dermatol Epub2017621
   Web of Science ®Google Scholar
• PappKThaciDReichKTildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo controlled trialBr J Dermatol201517393093926042589
   PubMed Web of Science ®Google Scholar
• ReichKPappKBlauveltATildrakizumab versus placebo or etanecept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomized, controlled phase 3 trialsLancet20173901009127628828596043
   PubMed Web of Science ®Google Scholar
• KruegerJGFerrisIKMenterAAnti-IL23A mAb BI655066 for treatment of moderate to severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single dose randomised double blind placebo controlled trialJ Allergy Clin Immunol201513611612425769911
   PubMed Web of Science ®Google Scholar
• PappKMenterASofenHEfficacy and safety of different dose regimens of a novel selective IL23p19 inhibitor (BI655066) compared with ustekinumab in patients with moderate-to-severe psoriasisAbstract presented at: 73rd Annual Meeting of American Academy of DermatologyMarch 20–24, 2015San Francisco, CA
   Google Scholar
• SinghSKroe-BarrettRRCanadaKASelective targeting of the IL23 pathway: generation and characterization of a novel high-affinity humanized anti-IL-23A antibodymAbs20157477879125905918
   PubMed Web of Science ®Google Scholar